Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline Portfolio News / By Karina Tin January 10, 2022
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones Portfolio News / By Karina Tin January 10, 2022
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts Portfolio News / By Karina Tin January 10, 2022
Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team Portfolio News / By Karina Tin January 6, 2022
Escient Pharmaceuticals Appoints Joshua Grass, MBA As CEO Portfolio News / By Karina Tin January 5, 2022
Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Portfolio News / By Karina Tin December 23, 2021
Remix Therapeutics Appoints Zaven Kaprielian, Ph.D., as Chief Scientific Officer Portfolio News / By Karina Tin December 15, 2021
Neurona Therapeutics Announces C-Suite Leadership Team Portfolio News / By Karina Tin December 13, 2021
ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting Portfolio News / By Karina Tin December 13, 2021